Back to LCT Homepage Targeting Huntington's Disease, Stroke, Type 1 Diabetes and Haemophilia
Living Cell Technologies
LCT - Living Cell Technologies

News

News updates: Subscribe
Unsubscribe

Archive

July 22, 2008
LCT Reports Clinical Benefits
>more
July 17, 2008
LCT Hosts Seminar of World Leaders
>more
July 14, 2008
LCT Quarterly Newsletter
>more
July 11, 2008
Transcript of LCT interview with The Wall Street
>more
June 26, 2008
LCT Informed of Progress for Diabetes Clinical Trial
>more
 

News

LCT announces underwriting of share purchase plan
February 2, 2007

Living Cell Technologies (ASX:LCT) announced today that its current Share Purchase Plan offer will be underwritten by Australasian share-broking firm Taylor Collison to the value of AUD$3 million.

Related Document
Download ( = 53Kb )

LCT - Living Cell Technologies

Q & A

What is xenotransplantation?
The use of living animal cells, tissues or organs in human therapeutics. >more

What is DiabeCell?
DiabeCell is a porcine pancreatic cell product for the treatment of insulin-dependent diabetes. >more

What is NeurotrophinCell?
A choroid plexus (brain) cell product with the potential to treat diseases of the nervous system such as Huntington's disease and stroke. >more

What is LCT's encapsulation technology?
The living cells are covered in a seaweed-derived coating (alginate encapsulation) to form capsules which eliminate the
need for toxic immunosuppressant drugs and allow the release of beneficial factors. >more
 
HomeContactSitemapLegalsPrivacy
  
graphic design and website design - PDF Communications Ltd